{"brief_title": "Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient", "brief_summary": "To make intravenous (IV) ganciclovir available to immunocompromised patients with life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of the disease are too severe to allow admission to a controlled clinical study of ganciclovir therapy. To determine the safety and tolerance of 2 - 3 weeks induction course of ganciclovir IV followed by a maintenance course of ganciclovir IV for an indefinite duration. To tabulate the patient's clinical response.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Ganciclovir", "criteria": "Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Cytomegalovirus (CMV) disease who meet the criteria for a treatment IND protocol, or other clinical studies, including controlled clinical studies of anticytomegalovirus therapy in peripheral CMV retinitis in patients with AIDS. - Mild to moderate CMV infections who fail to meet the severity criteria. CMV syndrome (i.e., cytopenia, increased liver enzymes, fever, viremia, viruria) is not considered immediately life-threatening. - Transplant patients in whom trial reduction of immunosuppressive drug treatment is feasible. - Children with congenital or neonatal CMV where there is not a documented primary or acquired immunodeficiency. - Hypersensitivity to acyclovir or ganciclovir. - Receiving antimetabolite treatment that cannot be discontinued. Concurrent Medication: Excluded: - Antimetabolites. - Alkylating agents. - Nucleoside analogs (topical ophthalmics are permitted). - Interferon. - Foscarnet. - Cytokines. Patients with the following are excluded: - Cytomegalovirus (CMV) infection who meet the criteria for a treatment IND protocol, or other clinical studies, including controlled clinical studies of anticytomegalovirus therapy in peripheral CMV retinitis in patients with AIDS. - Mild to moderate CMV infections who fail to meet the severity criteria. CMV syndrome (i.e., cytopenia, increased liver enzymes, fever, viremia, viruria) is not considered immediately life-threatening. - Transplant patients in whom trial reduction of immunosuppressive drug treatment is feasible. - Children with congenital or neonatal CMV where there is not a documented primary or acquired immunodeficiency. - Hypersensitivity to acyclovir or ganciclovir. - Receiving antimetabolite treatment that cannot be discontinued. Patients must qualify as follows: - Previously enrolled in compassionate use study (ICM 1257/1257A) or have terminated from another Syntex ganciclovir study. - Diagnosis of AIDS and life-threatening Cytomegalovirus (CMV) infection. - Diagnosis of other immunodeficiencies other than AIDS, with life-threatening or sight-threatening CMV disease.", "gender": "All", "minimum_age": "3 Months", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002025.xml"}